Trial results

$TGTX — BRIUMVI (ublituximab)

TG THERAPEUTICS, INC. (TGTX) BRIUMVI (ublituximab): trial results in Relapsing multiple sclerosis (RMS), 2026.

Research by Catalyst Intel

The catalyst

"Topline data from the Phase 3 trial is expected around year-end 2026 or first quarter 2027."

— TG Therapeutics, Inc., 10-Q filed 2026-11-09 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

TGTX-BRIUMVIUBLIT-2026

Company

TG THERAPEUTICS, INC.

Kind

Trial results

Indication

Relapsing multiple sclerosis (RMS)

Window

2026-01-01 – 2026-12-31

Status

slate

The bar

No bar has been published for this event yet.

Verdicts

Sealed with the bar. Any verdict for this event reaches this page on 2027-01-30; subscribers get it on the day.